- Home
- GNFT vs FDMT Comparison
GNFT vs FDMT Comparison
Compare GNFT & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- FDMT
- Stock Information
- Founded
- GNFT 1999
- FDMT 2013
- Country
- GNFT France
- FDMT United States
- Employees
- GNFT N/A
- FDMT N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- FDMT Health Care
- Exchange
- GNFT Nasdaq
- FDMT Nasdaq
- Market Cap
- GNFT 214.5M
- FDMT 192.2M
- IPO Year
- GNFT 2019
- FDMT 2020
- Fundamental
- Price
- GNFT N/A
- FDMT $4.24
- Analyst Decision
- GNFT Strong Buy
- FDMT Buy
- Analyst Count
- GNFT 1
- FDMT 10
- Target Price
- GNFT $13.00
- FDMT $32.33
- AVG Volume (30 Days)
- GNFT 4.2K
- FDMT 538.6K
- Earning Date
- GNFT 04-24-2025
- FDMT 08-07-2025
- Dividend Yield
- GNFT N/A
- FDMT N/A
- EPS Growth
- GNFT N/A
- FDMT N/A
- EPS
- GNFT 0.03
- FDMT N/A
- Revenue
- GNFT $73,187,701.00
- FDMT $23,000.00
- Revenue This Year
- GNFT $15.98
- FDMT $13,048.65
- Revenue Next Year
- GNFT N/A
- FDMT N/A
- P/E Ratio
- GNFT $125.30
- FDMT N/A
- Revenue Growth
- GNFT 105.01
- FDMT N/A
- 52 Week Low
- GNFT $2.55
- FDMT $2.24
- 52 Week High
- GNFT $6.42
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- GNFT 47.81
- FDMT 55.56
- Support Level
- GNFT $3.61
- FDMT $3.68
- Resistance Level
- GNFT $3.95
- FDMT $4.40
- Average True Range (ATR)
- GNFT 0.14
- FDMT 0.27
- MACD
- GNFT -0.01
- FDMT -0.02
- Stochastic Oscillator
- GNFT 57.01
- FDMT 59.57
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.